Novartis will pay $75 million upfront and Sangamo is eligible to earn up to $720 million in other development and commercial milestone payments. Sangamo is also eligible to receive from royalties on potential sales of products arising from the collaboration.
Sangamo’s ZFP-TF genome regulation technology, which is currently delivered with adeno-associated viruses (AAVs), functions at the DNA level to selectively repress or activate the expression of specific genes to achieve a desired therapeutic effect. The collaboration will leverage ZFP-TFs engineered by Sangamo in an effort to upregulate, or activate, the expression of genes that are inadequately expressed in individuals with certain types of neurodevelopmental disorders.
Over a three-year collaboration period, Novartis has exclusive rights to ZFP-TFs targeted to three undisclosed genes associated with neurodevelopmental disorders, including ASD and intellectual disability. Novartis also has the option to license Sangamo’s proprietary AAVs. Sangamo is responsible for certain research and associated manufacturing activities, which will be funded by Novartis, and Novartis assumes responsibility for additional research activities, clinical development, regulatory interactions, manufacturing and global commercialization.